StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) from a sell rating to a hold rating in a report published on Monday morning.
Separately, Piper Sandler initiated coverage on Lexicon Pharmaceuticals in a research note on Friday, August 12th. They issued an overweight rating and a $10.00 target price on the stock.
Get
Lexicon Pharmaceuticals alerts:
Lexicon Pharmaceuticals Stock Down 4.1 %
Shares of LXRX opened at $2.13 on Monday. Lexicon Pharmaceuticals has a 52 week low of $1.31 and a 52 week high of $5.22. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $401.99 million, a price-to-earnings ratio of -3.44 and a beta of 1.36. The stock's 50-day moving average price is $2.24 and its 200-day moving average price is $2.32.
Institutional Trading of Lexicon Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Bank of Montreal Can acquired a new position in Lexicon Pharmaceuticals in the 1st quarter worth about $26,000. Virtu Financial LLC acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $32,000. The Manufacturers Life Insurance Company acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $38,000. Tower Research Capital LLC TRC raised its holdings in Lexicon Pharmaceuticals by 214.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 19,389 shares of the biopharmaceutical company's stock worth $46,000 after purchasing an additional 13,232 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in Lexicon Pharmaceuticals by 76.8% in the 3rd quarter. Victory Capital Management Inc. now owns 20,433 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 8,873 shares during the period.
About Lexicon Pharmaceuticals
(Get Rating)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
Further Reading
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Rating) from a sell rating to a hold rating in a report published on Monday morning.
斯托克新闻网在周一上午发布的一份报告中将Licion PharmPharmticals(纳斯达克代码：LXRX-GET Rating)的股票评级从卖出上调至持有。
Separately, Piper Sandler initiated coverage on Lexicon Pharmaceuticals in a research note on Friday, August 12th. They issued an overweight rating and a $10.00 target price on the stock.
另外，派珀·桑德勒在8月12日星期五的一份研究报告中对Licion PharmPharmticals进行了报道。他们对该股发布了增持评级和10.00美元的目标价。
Get
Lexicon Pharmaceuticals
alerts:
Lexicon Pharmaceuticals Stock Down 4.1 %
Shares of LXRX opened at $2.13 on Monday. Lexicon Pharmaceuticals has a 52 week low of $1.31 and a 52 week high of $5.22. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $401.99 million, a price-to-earnings ratio of -3.44 and a beta of 1.36. The stock's 50-day moving average price is $2.24 and its 200-day moving average price is $2.32.
周一，LXRX的股价开盘报2.13美元。Licion PharmPharmticals的52周低点为1.31美元，52周高位为5.22美元。该公司的速动比率为7.54，流动比率为7.54，债务权益比率为0.17。该公司市值为4.0199亿美元，市盈率为-3.44倍，贝塔系数为1.36。该股的50日移动均线价格为2.24美元，200日移动均线价格为2.32美元。
Institutional Trading of Lexicon Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Bank of Montreal Can acquired a new position in Lexicon Pharmaceuticals in the 1st quarter worth about $26,000. Virtu Financial LLC acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $32,000. The Manufacturers Life Insurance Company acquired a new position in Lexicon Pharmaceuticals in the 3rd quarter worth about $38,000. Tower Research Capital LLC TRC raised its holdings in Lexicon Pharmaceuticals by 214.9% in the 3rd quarter. Tower Research Capital LLC TRC now owns 19,389 shares of the biopharmaceutical company's stock worth $46,000 after purchasing an additional 13,232 shares during the period. Finally, Victory Capital Management Inc. raised its holdings in Lexicon Pharmaceuticals by 76.8% in the 3rd quarter. Victory Capital Management Inc. now owns 20,433 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 8,873 shares during the period.
对冲基金最近调整了对该股的持有量。蒙特利尔银行可以在第一季度收购Licion PharmPharmticals的一个新头寸，价值约2.6万美元。Virtu Financial LLC在第三季度收购了Licion PharmPharmticals的一个新头寸，价值约3.2万美元。制造商人寿保险公司在第三季度收购了Licion制药公司的一个新头寸，价值约3.8万美元。Tower Research Capital LLC TRC在第三季度将其在Licion PharmPharmticals的持股增加了214.9%。Tower Research Capital LLC TRC现在拥有这家生物制药公司19389股股票，价值46,000美元，在此期间又购买了13,232股。最后，胜利资本管理公司在第三季度将其在Licion PharmPharmticals的持股增加了76.8%。胜利资本管理公司现在持有20,433股这家生物制药公司的股票，价值49,000美元，在此期间又购买了8,873股。
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain.
Licion制药公司是一家生物制药公司，专注于药品的发现、开发和商业化。该公司正在开发的口服小分子药物候选药物包括用于治疗心力衰竭和1型糖尿病的已完成第三阶段临床试验的索他利氟秦；以及用于治疗神经病理性疼痛的LX9211。
Further Reading
- Get a free copy of the StockNews.com research report on Lexicon Pharmaceuticals (LXRX)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- 免费获取StockNews.com关于Licion PharmPharmticals(LXRX)的研究报告
- 三只CBD股票将主宰一个萌芽行业
- 机构对ADI的支持仍然很高
- 60/40的投资组合组合还在《时尚》杂志上流行吗？
- 微软股票：是时候备份卡车了吗？
- Salesforce裁员，尽管面临挑战，但收入强劲
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Licion PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Licion制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。
